DUBLIN, Nov. 13, 2023 /PRNewswire/ -- More than half (51%) of U.S. adults are optimistic new applications of artificial intelligence (AI) will lead to major advancements and breakthroughs in healthcare in the year ahead, according to a new survey from Medtronic, a global healthcare technology leader, and Morning Consult.
Some of the highest levels of optimism for AI in healthcare are around diagnoses and improving healthcare access. In fact, roughly six in ten adults (61%) agree one of the main benefits of using AI in healthcare is to diagnose and detect health conditions. Further, approximately two-thirds (65%) of adults agree technology can help break down barriers to healthcare with more than half (56%) saying AI (specifically) can be beneficial in improving healthcare access.
"Disruptive technologies like AI alter the trajectories of our daily lives, changing how we shop, how we communicate, and how we receive healthcare," shares Ken Washington, chief technology and innovation officer at Medtronic. "While skepticism is natural, the survey found strong optimism around the potential of AI in healthcare. And the reality is, the way we engage with AI will likely look radically different five to 10 years from now. That said, there is one thing I'm certain of — the responsible, ethical use of AI has the power to radically improve healthcare for both patients and doctors."
Addressing perceived barriers to AI adoption is key to increasing consumer confidence
While more than half of Americans are optimistic about AI, there are still barriers to overcome. Among survey respondents who are skeptical about the technology, they report having more proof around AI's potential could help them be more confident in the technology.
Americans want to know their doctor is calling the shots – not AI
Consumers have a favorable opinion of using AI to manage their health – but report they aren't ready for their physician to use it extensively, with the survey showing that:
"Here's the bottom line — AI can't be a substitute for human judgement and experience. To this end, I cannot imagine a future where AI will replace doctors. But I can envision a future where AI is ubiquitous in healthcare, creating better experiences and outcomes that patients will prefer," adds Washington.
Medtronic has been pioneering the research and development of AI-based technology for more insights-driven care, from diagnosis to treatment to monitoring. Here are few examples of AI in action at Medtronic today.
Washington will be sharing more of his perspective on AI in healthcare and these survey findings during this week's Techonomy23 conference taking place in Orlando, FL.
For more information on Medtronic's commitment to advancing healthcare through technology and examples of the impact of their AI-based solutions, visit Medtronic.com.
About the Consumer Perceptions of AI Survey
The survey was conducted by decision intelligence company Morning Consult among a nationally representative sample of 2,213 adults in the U.S. from September 27-30, 2023, with an unweighted margin of error of +/- 2 percentage points.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts: | |
Erika Winkels | Ryan Weispfenning |
Public Relations | Investor Relations |
+1-763-526-8472 | +1-736-505-4626 |
Last Trade: | US$87.53 |
Daily Change: | 1.53 1.78 |
Daily Volume: | 6,417,026 |
Market Cap: | US$112.040B |
November 01, 2024 October 28, 2024 October 24, 2024 September 25, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB